- Home
- BIIB vs WAT Comparison
BIIB vs WAT Comparison
Compare BIIB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- WAT
- Stock Information
- Founded
- BIIB 1978
- WAT 1958
- Country
- BIIB United States
- WAT United States
- Employees
- BIIB N/A
- WAT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- BIIB Health Care
- WAT Industrials
- Exchange
- BIIB Nasdaq
- WAT Nasdaq
- Market Cap
- BIIB 25.1B
- WAT 22.5B
- IPO Year
- BIIB 1991
- WAT 1995
- Fundamental
- Price
- BIIB $158.15
- WAT $382.46
- Analyst Decision
- BIIB Buy
- WAT Hold
- Analyst Count
- BIIB 25
- WAT 13
- Target Price
- BIIB $258.57
- WAT $363.92
- AVG Volume (30 Days)
- BIIB 1.6M
- WAT 528.9K
- Earning Date
- BIIB 10-30-2024
- WAT 11-01-2024
- Dividend Yield
- BIIB N/A
- WAT N/A
- EPS Growth
- BIIB 10.05
- WAT N/A
- EPS
- BIIB 11.06
- WAT 10.48
- Revenue
- BIIB $9,607,500,000.00
- WAT $2,905,147,000.00
- Revenue This Year
- BIIB N/A
- WAT $0.53
- Revenue Next Year
- BIIB N/A
- WAT $5.59
- P/E Ratio
- BIIB $14.41
- WAT $37.36
- Revenue Growth
- BIIB N/A
- WAT N/A
- 52 Week Low
- BIIB $153.62
- WAT $279.24
- 52 Week High
- BIIB $268.30
- WAT $395.50
- Technical
- Relative Strength Index (RSI)
- BIIB 35.55
- WAT 57.38
- Support Level
- BIIB $158.31
- WAT $380.14
- Resistance Level
- BIIB $162.62
- WAT $395.50
- Average True Range (ATR)
- BIIB 3.00
- WAT 10.39
- MACD
- BIIB 1.00
- WAT 0.23
- Stochastic Oscillator
- BIIB 48.60
- WAT 79.37
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.